viewMidatech Pharma PLC

Midatech Pharma says next 12-18 months will be a "transformational period" for the company

The company is well funded with £9mln in the bank at the end of the first half

Midatech Pharma PLC -

Midatech Pharma PLC (LON:MTPH) expects the next 12-18 months to be a “transformational period” for the company with its two key products moving into the final stages of their clinical development.

“We are excited at the prospect of our products progressing in the clinic and making a difference for patients and create value for our shareholders,” the company said alongside interim results.

Its two key drug candidates are MTD201 and MTX110.

The former is being developed to treat acromegaly, where the body produces too much growth hormone, and neuroendocrine tumours, which affect hormone-releasing cells. A development plan is currently being finalised following a successful phase I trial.

MTX110 has been created to treat an aggressive brain cancer called diffuse intrinsic pontine glioma, which affects children. A first-in-human study “continues to progress well”, Midatech said. It has been well tolerated by patients so far. The dose-escalation part of the trial is set to conclude in the fourth quarter to be followed by a phase II assessment of efficacy.

Investment by China Medical Systems (CMS), along with a share placing, brought in £13.4mln, which secures the firm’s cash runway “into 2020”.

It has also received the promise of public finance for the scale-up operations in the Basque region of Spain.

As is common for companies at this formative stage of development, Midatech was loss-making. The loss from continuing operations fell £1.2mln to £4.42mln as administrative and R&D costs fell year on year in the six months ended June 30. The cash balance as of that date was £9mln.

“The first half of this year saw us achieve some important milestones,” said chief executive Craig Cook.

“Alongside a successful fundraise we secured our largest ever licensing partnership for our technology with CMS. 

“We have moved our in-house programmes forward and now have a clear, deliverable development plan for our lead product MTD201, together with the exciting potential of our MTX110 programme, with further clinical data expected from both programmes in the near term."

Quick facts: Midatech Pharma PLC

Price: 30 GBX

Market: AIM
Market Cap: £7.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Midatech Pharma PLC named herein, including the promotion by the Company of Midatech Pharma PLC in any Content on the Site, the Company...



Investor Update: accesso Technology announces deal with The New York...

Top stories from the Proactive Investors UK newsroom: accesso Technology Group PLC (LON:ACSO) has signed a three-year partnership with The New York Botanical Garden (NYBG) to supply its Passport, Siriusware and Ingresso products. Based near The Bronx, the NYBG attracts over 1mln visitors...

on 13/6/19

2 min read